Gyre Therapeutics (GYRE) Current Leases (2019 - 2026)
Gyre Therapeutics (GYRE) reported Current Leases of $751000.0 for Q1 2026, down 6.71% year-over-year from $805000.0 in Q1 2025, and up 18.08% quarter-over-quarter from $636000.0 in Q4 2025.
Gyre Therapeutics (GYRE) Current Leases (2019 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has 8 years of Current Leases data on file, last reported at $751000.0 in Q1 2026.
- Current Leases for Q1 2026 came in at $751000.0, down 6.71% year-over-year; the trailing twelve-month figure through Mar 2026 was $751000.0 (down 6.71% YoY), and the FY2025 annual result was $636000.0, down 10.8% from the prior year.
- Current Leases climbed to $751000.0 in Q1 2026 per GYRE's latest filing, from $636000.0 in the prior quarter.
- Over five years, Current Leases peaked at $1.9 million in Q1 2022 and troughed at $100000.0 in Q1 2024.
- A 5-year average of $715214.3 and a median of $647500.0 in 2024 frame the typical range for Current Leases.
- The sharpest annual moves came in 2022 and 2025: Current Leases plunged 79.34% in 2022, then jumped 705.0% in 2025.
- A 5-year view of Current Leases shows it stood at $492000.0 in 2022, then slumped by 57.32% to $210000.0 in 2023, then surged by 239.52% to $713000.0 in 2024, then dropped by 10.8% to $636000.0 in 2025, then rose by 18.08% to $751000.0 in 2026.
- Business Quant data shows GYRE's Current Leases at $751000.0 in Q1 2026, $636000.0 in Q4 2025, and $626000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 42,980.09 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 83,991.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 7.40 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Gyre Therapeutics | 554.75 Mn | 540.62 Mn | 8.38 Mn | 751,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 751,000.00 |
| Dec 31, 2025 | 636,000.00 |
| Sep 30, 2025 | 626,000.00 |
| Jun 30, 2025 | 622,000.00 |
| Mar 31, 2025 | 805,000.00 |
| Dec 31, 2024 | 713,000.00 |
| Sep 30, 2024 | 694,000.00 |
| Jun 30, 2024 | 659,000.00 |
| Mar 31, 2024 | 100,000.00 |
| Dec 31, 2023 | 210,000.00 |
| Dec 31, 2022 | 492,000.00 |
| Sep 30, 2022 | 381,000.00 |
| Jun 30, 2022 | 1.42 Mn |
| Mar 31, 2022 | 1.91 Mn |
| Dec 31, 2021 | 1.98 Mn |
| Sep 30, 2021 | 1.84 Mn |
| Jun 30, 2021 | 1.81 Mn |
| Mar 31, 2021 | 678,000.00 |
| Dec 31, 2020 | 663,000.00 |
| Sep 30, 2020 | 519,000.00 |